The Phase Ib/II trial assessed evorpacept plus zanidatamab in previously treated, metastatic HER2-expressing cancers.

"Among the patients with matched samples from breast primary and metastatic sites in this study, there was a significant level of discordance in HER2 expression." — Megan Kruse, MD A team from the ...

New data from a phase 1b/2 clinical trial shows that a specific protein called CD47 can help predict how well the investigational drug evorpacept works for patients with metastatic breast cancer, ALX ...

CD47 expression levels may predict evorpacept efficacy in HER2-positive metastatic breast cancer, especially in heavily pretreated patients. Evorpacept combined with zanidatamab shows promising ...

Optimal management recommendations for patients with HER2 low breast cancer are unclear/unknown. Patients with HER2-low tumors in the new study accounted for more than half of all early breast cancer ...

bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study. The level of TS expression was evaluated in 210 node-negative and 278 ...